Ryan Montano

Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites

Ryan Montano, Injae Chung, Kristen M. Garner et al. · Molecular Cancer Therapeutics · 2011 · 117 citations · Full text

Cell Death, Molecular Biology, Cell Cycle +16

Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo

Ryan Montano, Ruth Thompson, Injae Chung et al. · BMC Cancer · 2013 · 75 citations · Full text

A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase

Nandini Sakurikar, Ruth Thompson, Ryan Montano et al. · Oncotarget · 2015 · 74 citations · Full text

The Mre11 Nuclease Is Critical for the Sensitivity of Cells to Chk1 Inhibition

Ruth Thompson, Ryan Montano, Alan Eastman · PLoS ONE · 2012 · 55 citations · Full text

U2os Osteosarcoma Cells, Molecular Biology, Cell Death +19

Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor

Ryan Montano, Nadeem Khan, Huagang Hou et al. · Oncotarget · 2017 · 46 citations · Full text

Chemoprevention Strategy, Cell Death, Chk1 Inhibitor +16